In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody
- PMID: 15598985
In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody
Abstract
Rituximab, chimeric anti-human CD20 monoclonal antibody approved for B-cell lymphoma, depletes circulating B cells. Little data exist on its use for nonmalignant diseases or B-cell subset recovery after treatment. We hypothesized that rituximab may reduce panel reactive alloantibodies (PRA) in dialysis patients awaiting renal transplantation and performed a single-dose, dose-escalation phase 1 trial. Here we report changes in lymphocyte phenotypes in subjects treated with rituximab alone. Nine subjects, 44 +/- 10 years(Yr); (5 F, 4 M) received one dose (n=3) at 50, 150, or 375 mg/m(2) without other immunosuppression. Blood was collected before dosing and intervals thereafter. No significant changes in leukocytes, total or CD3(+) lymphocytes were noted. In all, there was CD19(+) depletion by day 2(D2) (12.0 +/- 5.6 cells/mm(3) vs. 181 +/- 137, D0; p<0.01) and CD20(+) (11.0 +/- 12.0 vs. 205 +/- 116, D0; p<0.01). At 6 months (mo), CD19(+) and CD20(+) remained low (51.1 +/- 42.2, p<0.05; 75.4 +/- 38.7, p<0.05, respectively) compared to D0. CD19(+)CD5(+) cells recovered more rapidly, returning to baseline by 6mo while B memory cells (CD19(+)CD27(+)) remained low (32.3 +/- 29.0) at 1Yr (7.5 +/- 4.5; p<0.001) and 2Yr (12.1 +/- 7.9; p<0.001) after treatment. We conclude that single dose rituximab ablates B cells in high PRA dialysis patients awaiting transplantation. B-cell ablation, particularly memory B cells, was long-lasting, lagging repopulation by CD5(+) B cells.
Similar articles
-
Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.Clin Immunol. 2008 Jun;127(3):280-5. doi: 10.1016/j.clim.2008.01.011. Epub 2008 Mar 11. Clin Immunol. 2008. PMID: 18337174 Review.
-
BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.Arthritis Rheum. 2007 May;56(5):1464-77. doi: 10.1002/art.22603. Arthritis Rheum. 2007. PMID: 17469105 Clinical Trial.
-
Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.Arthritis Rheum. 2006 Aug;54(8):2377-86. doi: 10.1002/art.22019. Arthritis Rheum. 2006. PMID: 16869000
-
Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.Br J Dermatol. 2005 Jul;153(1):167-73. doi: 10.1111/j.1365-2133.2005.06659.x. Br J Dermatol. 2005. PMID: 16029344 Review.
-
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus.Arthritis Rheum. 2004 Nov;50(11):3580-90. doi: 10.1002/art.20592. Arthritis Rheum. 2004. PMID: 15529346 Clinical Trial.
Cited by
-
Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination.Clin Case Rep. 2021 Aug 16;9(8):e04517. doi: 10.1002/ccr3.4517. eCollection 2021 Aug. Clin Case Rep. 2021. PMID: 34429981 Free PMC article.
-
Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab.BMC Nephrol. 2020 Mar 11;21(1):93. doi: 10.1186/s12882-020-01750-8. BMC Nephrol. 2020. PMID: 32160881 Free PMC article.
-
Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts.Front Immunol. 2020 Feb 5;11:79. doi: 10.3389/fimmu.2020.00079. eCollection 2020. Front Immunol. 2020. PMID: 32117242 Free PMC article. Clinical Trial.
-
B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapy.J Transl Med. 2017 Jan 13;15(1):9. doi: 10.1186/s12967-017-1118-7. J Transl Med. 2017. PMID: 28086979 Free PMC article. Clinical Trial.
-
The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival.J Immunol Res. 2016;2016:7473239. doi: 10.1155/2016/7473239. Epub 2016 Dec 12. J Immunol Res. 2016. PMID: 28058267 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials